Technology & Software Global On demand · 24-48h

Global Anemia Screening Test Market Strategic Research Report

Global Anemia Screening Test Market Strategic Research Repor…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Anemia Screening Test Market
$1.72B2025
6.4%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Whole Blood Test, Serum/Plasma Test

By Application: Medical and Health, Physical Examination, Public Health, Maternal and Child Health, Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Quest Diagnostics, Labcorp, Eurofins Scientific, Sonic Healthcare, SYNLAB International, Unilabs, Abbott Diagnostics, Roche Diagnostics, Siemens Healthineers, Beckman Coulter, Sysmex, Shenzhen Mindray Bio-Medical Electronics, Abbott Point of Care, Bio-Rad Laboratories, Streck Inc., Daktari Diagnostics, BIOMEDOMICS, Request A Test Ltd, HemoCue India, HEALTH Gene Technology, Walk‑In Lab, Southside Pediatrics, Uber Diagnostics, SYNLAB

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 153 pages
Market size 2025
$1.72B
Billion USD
Forecast CAGR
6.4%
2025-2032
Forecast 2032
$2.7B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Anemia Screening Test market size is predicted to grow from US$ 1,719 million in 2025 to US$ 2,643 million in 2032; it is expected to grow at a CAGR of 6.4% from 2026 to 2032.

To address the challenges associated with traditional anemia detection—specifically the time-consuming nature of routine blood tests, the susceptibility of results to human error, and the low screening coverage rates resulting from a scarcity of medical resources in remote areas—anemia screening technologies have emerged. Since the breakthrough in quantitative hemoglobin detection methods in the 1950s, this field has evolved into a comprehensive screening system encompassing rapid testing, precise classification, and dynamic monitoring, driven by the integration of automated blood analyzers, the development of portable testing devices, and AI-assisted diagnostic technologies. This technology is now widely applied across various sectors, including routine clinical screening, primary healthcare, specialized operational environments, and home-based self-testing.

Anemia screening serves as a foundational tool in clinical diagnosis. Driven by the dual forces of technological innovation and market demand, the industry is currently undergoing a transformation, upgrading from "empirical diagnosis" to "precision medicine." Enterprises possessing independent innovation capabilities and the ability to integrate the entire industry value chain are poised to lead this transformation, while those lacking core technologies face the risk of obsolescence. Looking ahead, non-invasive testing, AI-assisted diagnostics, and home-based self-testing devices are expected to become the new engines of growth, propelling the industry toward greater efficiency and broader inclusivity.

This report presents a comprehensive overview of the global Anemia Screening Test market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Whole Blood Test
  • Serum/Plasma Test

Segment by Detection Indicators

  • Hemoglobin Count
  • Reticulocyte Count

Segment by Data Interpretation

  • Qualitative Analysis
  • Quantitative Monitoring

Segment by Application

  • Medical and Health
  • Physical Examination
  • Public Health
  • Maternal and Child Health
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Anemia Screening Test market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical and Health, Physical Examination, Public Health evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Anemia Screening Test Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 6.4%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.72B
2025
Forecast
$2.7B
2032
CAGR
6.4%
2025–2032
Regiones
5
global
Key companies
Quest DiagnosticsLabcorpEurofins ScientificSonic HealthcareSYNLAB InternationalUnilabsAbbott DiagnosticsRoche Diagnostics
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Whole Blood TestSerum/Plasma Test
By Application
Medical and HealthPhysical ExaminationPublic HealthMaternal and Child HealthOther

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Whole Blood Test
  • 3.1.3 Serum/Plasma Test
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical and Health
  • 4.1.3 Physical Examination
  • 4.1.4 Public Health
  • 4.1.5 Maternal and Child Health
  • 4.1.6 Other
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Quest Diagnostics
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Labcorp
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Eurofins Scientific
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Sonic Healthcare
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 SYNLAB International
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Unilabs
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Abbott Diagnostics
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Roche Diagnostics
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Siemens Healthineers
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Beckman Coulter
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Sysmex
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Shenzhen Mindray Bio-Medical Electronics
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Abbott Point of Care
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Bio-Rad Laboratories
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Streck Inc.
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Daktari Diagnostics
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 BIOMEDOMICS
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 Request A Test Ltd
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 HemoCue India
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 HEALTH Gene Technology
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
  • 8.21 Walk‑In Lab
  • 8.21.1 Company Overview
  • 8.21.2 Key Products & Segments
  • 8.21.3 Financial Performance (2023–2025)
  • 8.21.4 Business Strategy
  • 8.21.5 SWOT Analysis
  • 8.21.6 Strategic Implications (2026–2032)
  • 8.22 Southside Pediatrics
  • 8.22.1 Company Overview
  • 8.22.2 Key Products & Segments
  • 8.22.3 Financial Performance (2023–2025)
  • 8.22.4 Business Strategy
  • 8.22.5 SWOT Analysis
  • 8.22.6 Strategic Implications (2026–2032)
  • 8.23 Uber Diagnostics
  • 8.23.1 Company Overview
  • 8.23.2 Key Products & Segments
  • 8.23.3 Financial Performance (2023–2025)
  • 8.23.4 Business Strategy
  • 8.23.5 SWOT Analysis
  • 8.23.6 Strategic Implications (2026–2032)
  • 8.24 SYNLAB
  • 8.24.1 Company Overview
  • 8.24.2 Key Products & Segments
  • 8.24.3 Financial Performance (2023–2025)
  • 8.24.4 Business Strategy
  • 8.24.5 SWOT Analysis
  • 8.24.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Anemia Screening Test market?
The global Anemia Screening Test market is estimated at US$ 1.72 billion in 2025 (base year) and is projected to reach US$ 2.64 billion by 2032.
How fast is the Anemia Screening Test market expected to grow?
The market is expected to grow at a CAGR of 6.4% from 2026 to 2032, expanding from US$ 1.72 billion in 2025 to US$ 2.64 billion in 2032, roughly 1.5 times its base-year value.
What does the Anemia Screening Test market cover?
To address the challenges associated with traditional anemia detection—specifically the time-consuming nature of routine blood tests, the susceptibility of results to human error, and the low screening coverage rates resulting from a scarcity of medical resources in remote areas—anemia screening technologies have emerged. This technology is now widely applied across various sectors, including routine clinical screening, primary healthcare, specialized operational environments, and home-based self-testing.
How is the Anemia Screening Test market segmented by type?
By type, the market is segmented into Whole Blood Test and Serum/Plasma Test.
What are the key applications of Anemia Screening Test?
Key applications covered include Medical and Health, Physical Examination, Public Health, Maternal and Child Health and Other.
Which companies are profiled in the Anemia Screening Test market report?
Key players profiled include Quest Diagnostics, Labcorp, Eurofins Scientific, Sonic Healthcare, SYNLAB International, Unilabs, Abbott Diagnostics and Roche Diagnostics, among 24 companies covered in total.
What geographies does the Anemia Screening Test market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Anemia Screening Test?
Driven by the dual forces of technological innovation and market demand, the industry is currently undergoing a transformation, upgrading from "empirical diagnosis" to "precision medicine." Enterprises possessing independent innovation capabilities and the ability to integrate the entire industry value chain are poised to lead this transformation, while those lacking core technologies face the risk of obsolescence.
What are the main risks and barriers in the Anemia Screening Test market?
To address the challenges associated with traditional anemia detection—specifically the time-consuming nature of routine blood tests, the susceptibility of results to human error, and the low screening coverage rates resulting from a scarcity of medical resources in remote areas—anemia screening technologies have emerged.
Who should buy the Anemia Screening Test market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical and Health, Physical Examination and Public Health, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Anemia Screening Test market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.